CD4 and myeloid sarcoma: The upregulated frequency of CD56+ cells at relapse in the F-MS group was also observed in both the CD4+ and CD8+ T cell subsets (the mean frequency, CD56+CD4+ T cells: 32.4% vs 5.3% p = 0.0029; CD56+CD8+ T cells: 72.6% vs 12.0%, p = 0.0015) (Fig. 1c).